MPAL Leukemia: Symptoms, Diagnosis, and Treatment

Mixed phenotype acute leukemia, or MPAL, is a rare and aggressive blood cancer in which the leukemia cells carry markers of more than one blood cell lineage, most often a mix of myeloid and lymphoid features. It accounts for roughly 4% of all acute leukemia cases, and its dual-identity biology makes every step harder, from getting the right diagnosis to choosing the right treatment.¹ Because MPAL does not fit neatly into either the AML or ALL category, it demands a diagnostic approach and treatment strategy that differ meaningfully from those used for more common leukemias.

What MPAL Looks Like at the Start

MPAL does not announce itself with unique symptoms. The signs are the same ones that accompany most acute leukemias, all driven by the bone marrow being overrun by abnormal blast cells that crowd out normal blood production. You can expect fever and frequent infections as white blood cell function drops, unexplained bruising or bleeding from low platelets, persistent fatigue and pale skin from anemia, and appetite loss with unintended weight loss. Some patients also develop a swollen liver or spleen, noticeable as fullness or discomfort in the upper abdomen.²

None of these symptoms point specifically to MPAL rather than to standard AML or ALL. The distinction only becomes apparent in the lab. That is part of the problem: because the symptoms overlap entirely with other acute leukemias, MPAL is sometimes initially treated as AML or ALL before the full immunophenotyping results come back, potentially costing valuable time.

Getting the Diagnosis Right

Diagnosing MPAL is technically demanding. The disease has gone by several names over the decades, including mixed lineage leukemia, bilineal leukemia, and biphenotypic leukemia, and older classification systems used scoring criteria that were sometimes arbitrary and gave too much weight to markers that were not truly lineage-specific.³ The current WHO classification, refined in 2008 and updated in 2016, simplified things by relying on fewer, more reliable markers. Under these criteria, myeloid lineage is identified mainly by the presence of myeloperoxidase, B-lymphoid lineage by strong CD19 expression, and T-lymphoid lineage by cytoplasmic CD3.⁴

The workhorse of MPAL diagnosis is multiparameter flow cytometry, a technology that tags cells with fluorescent antibodies and reads which surface and intracellular markers each individual blast carries. Without a sufficiently broad antibody panel, MPAL can be missed entirely, and the blasts incorrectly assigned to a single lineage.⁵ That matters because treatment for straightforward ALL or AML differs from what works best in MPAL, particularly when it comes to transplant decisions.

The updated WHO criteria are stricter than the older European Group for Immunological Classification of Leukemias (EGIL) system, and the shift changed who qualifies for an MPAL diagnosis. Some patients previously classified as having biphenotypic acute leukemia now fall under myeloid-antigen-positive ALL, a categorization that can carry a more favorable prognosis and may not need the same aggressive consolidation with transplant.⁶ So the classification system a pathologist uses can directly influence the treatment you receive.

Two Faces, One Cell

A natural question is how a single leukemia can express markers from two different blood cell lineages at once. Research published in Nature traced the origin of MPAL to founding mutations that arise in very primitive blood progenitor cells, before the cell has committed to becoming either myeloid or lymphoid. Because the starting cell sits so high in the blood-forming hierarchy, its cancerous offspring can differentiate down either branch, producing the mixed immunophenotype seen under the microscope.⁷ The study also showed that different immunophenotypic populations within the same tumor share the same founding genetic mutations. The mix of cell types is not caused by piling up different genetic hits in different subclones; instead, the early mutations prime the cell for what researchers call “lineage promiscuity.”

More recent single-cell genomic work has reinforced this picture, showing that MPAL blasts are strongly enriched for stem cell gene signatures. The blasts resemble very immature, undifferentiated progenitors, and the acquisition of further mutations pushes them toward an even more primitive cell state rather than driving them toward a specific lineage.⁸ This stem-like quality may help explain why MPAL can be stubborn to treat: stem-like leukemia cells are often better at surviving chemotherapy and fueling relapse.

Common Genetic Findings

The B-lymphoid/myeloid subtype is by far the most common form of MPAL, followed by T-lymphoid/myeloid; T/B combinations are rare. Cytogenetic studies regularly turn up a complex karyotype (multiple chromosomal abnormalities), the Philadelphia chromosome translocation (BCR-ABL1), and deletions of chromosome 5q. Frequently mutated genes include TP53, RUNX1, WT1, FLT3, and ASXL1, many of which are also commonly altered in standard AML or myelodysplastic syndromes.⁹ One study of 28 MPAL patients found that more than half carried at least one biomarker that could potentially be targeted with existing drugs, a finding that has practical implications for salvage therapy when standard chemotherapy fails.

The Philadelphia chromosome deserves special mention. It appears in roughly 15 to 32% of MPAL patients, a far higher rate than in many other leukemia subtypes.¹⁰ Before tyrosine kinase inhibitors (TKIs) became available, Philadelphia-positive MPAL had a grim outlook. Since TKIs entered the picture, survival for this subgroup has improved dramatically, approaching outcomes similar to those seen in Philadelphia-positive ALL.¹⁰ A review of 59 Philadelphia-positive MPAL cases confirmed that this subtype tends to present as B/myeloid, is more common in adult men, and responds well to TKI-based ALL-type therapy. Higher white blood cell counts and chromosome 7 abnormalities were linked to worse outcomes in this group.¹¹

Choosing the Right Chemotherapy

Because MPAL straddles two lineages, one of the first treatment decisions is whether to use chemotherapy designed for AML or chemotherapy designed for ALL, or some hybrid of both. This question has been studied extensively, and the evidence tilts clearly in one direction. A systematic review and meta-analysis pooling over 300 WHO-defined MPAL patients found that starting with an ALL-type induction regimen produced a more than three-fold higher complete remission rate compared with AML-type induction. The survival advantage held as well: patients who started on ALL-type therapy had significantly better overall survival than those who started on AML-type regimens.¹²

Interestingly, the same meta-analysis showed that hybrid induction regimens, which combine elements of both AML and ALL protocols, did not outperform ALL-type therapy and in some analyses were actually associated with worse outcomes. When looking at long-term survival rather than just remission rates, patients who received hybrid therapy fared worse than those who received ALL-type therapy alone.¹² A separate multicenter retrospective study confirmed these findings: among 77 adult MPAL patients, those receiving ALL-like induction had a significantly better complete remission rate than those receiving AML-like induction.¹³

This preference for ALL-type therapy holds across both adults and children. A comparative study of over 100 MPAL patients, split roughly evenly between pediatric and adult cases, found that ALL-like regimens produced better response rates in both age groups, with the advantage particularly pronounced in adults.¹ The finding aligns with the stem-like biology of MPAL: because the leukemic cells resemble very primitive progenitors rather than committed myeloid cells, they may be more vulnerable to the drugs used in ALL protocols.

When Transplant Becomes Part of the Plan

For many adult MPAL patients who achieve remission with chemotherapy, the next question is whether to consolidate with an allogeneic stem cell transplant, receiving donor stem cells to replace the patient’s bone marrow. The general trend in the data favors transplant for adults. One large retrospective study of the European transplant registry analyzed 195 adults with MPAL who underwent transplant in first complete remission. Two-year overall survival was about 71%, and leukemia-free survival was about 56%. The relapse rate at two years was roughly 30%, and non-relapse mortality (deaths from transplant complications rather than the leukemia itself) was about 14%.¹⁴

Within that study, the intensity of the transplant conditioning regimen mattered. Patients who received myeloablative conditioning, the more intensive option that fully destroys existing bone marrow before the transplant, had better overall survival and leukemia-free survival than those who received reduced-intensity conditioning. Peripheral blood was the preferred stem cell source over bone marrow, associated with lower relapse risk.¹⁴ A smaller series of 28 patients echoed the transplant benefit: the 10 patients who received an allogeneic transplant had significantly better outcomes than those who did not.⁹

The transplant question is less settled in children. Pediatric MPAL patients often do well on chemotherapy alone, especially when they achieve deep remissions early. Studies have shown that adults and children are managed differently in practice, with transplant used much more frequently in adults.¹⁵ This divergence makes sense given that transplant carries substantial risks, including graft-versus-host disease and long-term organ damage, which are especially consequential in a young patient who has decades of life ahead.

Targeted and Chemotherapy-Free Approaches

Because more than half of MPAL patients carry at least one potentially targetable mutation, interest in precision therapies has been growing. For Philadelphia-positive MPAL, TKIs like imatinib and dasatinib are already a standard component of therapy, and their addition to chemotherapy regimens has been associated with overall survival comparable to that of Philadelphia-positive ALL patients.¹⁶

For the subset of patients whose leukemia carries FLT3 mutations, newer inhibitors like gilteritinib are being tested. One case report described a patient with relapsed FLT3-mutant MPAL who achieved and maintained remission for eight months on a combination of gilteritinib and azacitidine, a hypomethylating agent.¹⁷ The evidence here is limited to individual case reports, not trials, but it points to a principle that applies more broadly: when a known drug target exists in MPAL, exploiting it can produce meaningful responses even after standard chemotherapy has failed.

Perhaps the most provocative development is the exploration of entirely chemotherapy-free regimens. A case series described two patients with B-lymphoid/myeloid MPAL carrying MLL-AF4 rearrangements who were treated with venetoclax (a BCL-2 inhibitor), a hypomethylating agent, and blinatumomab (a bispecific antibody that redirects the patient’s own T cells against CD19-positive blasts). Both achieved complete remission without any conventional cytotoxic chemotherapy.¹⁸ Two patients are far too few to draw firm conclusions, but the approach represents a shift in thinking: rather than treating MPAL with broad cytotoxic drugs and hoping the right lineage gets hit, these newer strategies use the tumor’s own molecular profile to select weapons.

What the Survival Numbers Look Like

MPAL carries a worse prognosis than either standard AML or ALL on average, though outcomes vary enormously depending on age, subtype, and treatment. A large real-world analysis of MPAL patients diagnosed between 2010 and 2021 found a sobering median overall survival of just 4.2 months across all subtypes when including patients of all ages and treatments. One-year survival was 37%, and five-year survival was 20%.¹⁹ These figures include many older patients who may not have been fit for intensive therapy, which pulls the overall numbers down considerably.

Age is the single strongest predictor. In the same dataset, patients aged 18 to 39 had a five-year survival of about 55%, while those 65 to 74 dropped to about 12%, and those over 75 had a five-year survival of just 2%.¹⁹ Subtype matters too. Philadelphia-positive MPAL stood out with the best outcomes, a median survival of nearly 54 months and a five-year survival approaching 49%, reflecting the benefit of TKI therapy. B/myeloid and T/myeloid subtypes without the Philadelphia chromosome had intermediate survival, while acute undifferentiated leukemia, a related ambiguous-lineage disease, had the worst outcomes of all.¹⁹

For patients who make it to transplant, the picture is considerably brighter. A five-year overall survival of about 54% was reported in a large transplant registry analysis that included patients transplanted in various disease statuses. Older age, poor performance status, being Philadelphia chromosome-negative, more advanced disease at the time of transplant, and lower-intensity conditioning were all associated with worse outcomes.²⁰ A prognostic model focused specifically on transplant patients identified stem cell engraftment and the absence of post-transplant relapse as the strongest predictors of three-year survival, which reached about 84% in the most favorable group.²¹

Tracking What You Cannot See

One of the unresolved challenges in MPAL is how to monitor for residual disease after treatment. In standard ALL, measuring minimal residual disease (MRD), the tiny fraction of leukemia cells that may survive chemotherapy, is a cornerstone of treatment decisions. Patients with high MRD after induction are known to have worse outcomes and may be fast-tracked to transplant. In MPAL, the rarity of the disease has made it difficult to gather enough data to integrate MRD monitoring into standard treatment protocols. The shifting diagnostic criteria between successive WHO classification systems only compound the problem, because a patient classified as MPAL under one system might not qualify under another.²²

This is not just an academic concern. If MPAL blasts express markers from two lineages, monitoring with a panel designed for only one lineage risks missing a residual population that has shifted its surface markers after therapy. The stem-like biology of MPAL, where cells can differentiate down multiple lineage paths, makes this a real possibility. Some centers now use broader flow cytometry panels after treatment to watch for lineage switching, but there is no universally adopted standard yet. Whether achieving MRD negativity should be an explicit goal of induction, as the multicenter Campus ALL study suggested, remains an area of active investigation.¹³

Why MPAL Remains Hard to Study

Nearly every treatment recommendation for MPAL comes with the caveat that the evidence base is thinner than clinicians would like. There are no completed large randomized controlled trials comparing regimens head-to-head in a population selected exclusively for MPAL. What exists is a patchwork of retrospective case series, registry analyses, and one meta-analysis of those smaller studies. The rarity of the disease, a few percent of all acute leukemias, makes traditional trial designs impractical. A single institution might see only a handful of cases per year.

This scarcity has real consequences. When a meta-analysis pools data from dozens of small series, each using slightly different diagnostic criteria and treatment protocols, the conclusions are directionally useful but leave room for uncertainty in any individual patient’s case. The diagnostic criteria themselves continue to evolve: the WHO 2016 revision made changes that reclassified some patients out of the MPAL category altogether, making historical comparisons tricky. And newer molecular technologies like single-cell sequencing are revealing biological complexity that the current classification system may not fully capture. As one group of researchers put it, a cell’s leukemic potential cannot be assigned by immunophenotype alone.⁸ Future classification systems may lean more heavily on genetic and transcriptomic profiles rather than surface marker expression, which could reshape how MPAL is defined, who receives the diagnosis, and what treatments are recommended.

1
PubMed. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients
2
St. Jude Children’s Research Hospital. Mixed Phenotype Acute Leukemia Treatment
3
PubMed. Mixed-phenotype acute leukemia: historical overview and a new definition
4
PubMed. An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)
5
PubMed Central. Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia
6
PubMed Central. Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia
7
PubMed Central. The genetic basis and cell of origin of mixed phenotype acute leukaemia
8
Nature Communications. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia
9
PubMed Central. Genomic Landscape of Mixed-Phenotype Acute Leukemia
10
Blood Research. Philadelphia-positive mixed phenotype acute leukemia presenting with PML-RARα fusion transcript without t(15;17) on cytogenetic studies
11
PubMed Central. Philadelphia chromosome-positive mixed-phenotype acute leukemia: a case report and literature review
12
PubMed Central. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis
13
PubMed. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
14
PubMed Central. Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMT
15
PubMed Central. Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia
16
Haematologica. Acute leukemia of ambiguous lineage: the known and the uncertain
17
PubMed Central. Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
18
Taylor & Francis Online (Immunotherapy). Chemotherapy-free treatment of B-lymphoid/myeloid mixed phenotype acute leukemia: two case reports and literature review
19
Blood. Outcomes Research: Myeloid Malignancies Mixed Phenotype Acute Leukemias: Real-World Outcomes By Who Classifications 2010-2021
20
Blood Neoplasia. Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia
21
PubMed Central. Development of a Prognostic Model for Survival of Mixed Phenotype Acute Leukaemia Patients Treated with Allogeneic Haematopoietic Stem Cell Transplantation
22
PubMed Central. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study